Related Experiment Video
Updated: Aug 10, 2026
Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
Published on: May 6, 2014
[Community-acquired pneumonia: attitude case of treatment failure]
1Departement de Médecine interne, Hôpital de la ville, 2300 La Chaux-de-Fonds. daniel.genne@ne.ch
Abstract:
It can be determined that for nearly one out of five patients hospitalized for a community-acquired pneumonia the empirical treatment chosen will fail. Those for whom the treatment failed face a bad outcome with a mortality rate as a high as 43%. Most causes of failure can be attributable to the patient rather than to the antibiotic or to the pathogen. The studies related to treatment failure show that resistance of the causal agent to antibiotic is rarely the cause, as opposed to discordant therapy (causal agent not covered by chosen antibiotherapy), which plays an important role. In these studies the multivariate analysis were able to show that concordant therapy (causal agent covered by chosen antibiotherapy), vaccination against influenza, monocytosis and old age were possible protective factors against treatment failure.
Insights
Empirical treatment failure for community-acquired pneumonia affects nearly 20% of patients, leading to high mortality. Patient factors, not antibiotic resistance, are the main cause, with discordant therapy playing a key role.
Area of Science:
- Infectious Diseases
- Clinical Medicine
- Pharmacology
Context:
- Community-acquired pneumonia (CAP) poses a significant global health challenge.
- Empirical antibiotic treatment is standard for CAP, but treatment failure rates are substantial.
- Understanding factors contributing to treatment failure is crucial for improving patient outcomes.
Purpose:
- To identify the primary causes of empirical antibiotic treatment failure in community-acquired pneumonia.
- To explore the role of discordant therapy versus antibiotic resistance in treatment outcomes.
- To determine potential protective factors against treatment failure in CAP patients.
Summary:
- Nearly 20% of hospitalized CAP patients experience empirical treatment failure, associated with up to 43% mortality.
- Treatment failure is predominantly linked to patient-related factors and discordant therapy, rather than pathogen antibiotic resistance.
- Concordant therapy, influenza vaccination, monocytosis, and older age were identified as potential protective factors against treatment failure.
Impact:
- Findings highlight the need to optimize empirical antibiotic selection and consider patient-specific factors to reduce CAP treatment failures.
- Improved understanding of failure mechanisms can guide clinical decision-making and potentially lower CAP-related mortality.
- This research underscores the importance of antimicrobial stewardship and personalized medicine approaches in managing infectious diseases.
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:14Atypical Pneumonia
01:29Pneumonia I: Introduction